Importantly, inhibition of the TGF‐β pathway with a dominant negative type II TGFβR, neutralizing TGF‐β antibodies, or soluble receptor variants in mesenchymal mouse colon carcinoma CT26 cell line was shown to decrease in vitro invasiveness and metastasis formation in tumor xenografts (Oft et al., 1998). Here, TGFB1 is linked to neoplasm.